A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache

Conditions:   Episodic Cluster Headache;   Chronic Cluster Headache
Intervention:   Drug: Galcanezumab
Sponsor:   Eli Lilly and Company
Enrolling by invitation – verified June 2017
Source: ClinicalTrials.gov Listing of Cluster Headache trials
The main purpose of this study is to assess the long-term safety and tolerability of galcanezumab administered up to once monthly in participants with episodic or chronic cluster headache who have completed study I5Q-MC-CGAL (NCT02397473) or study I5Q-MC-CGAM (NCT02438826).